Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Single Dose Pharmacokinetics of Temocapril (CS-622), a Novel Angiotensin Converting Enzyme (ACE) Inhibitor, in Partially Nephrectomised Rats

  • 3 Accesses

  • 2 Citations

Summary

The single dose pharmacokinetics of temocapril, a prodrug type angiotensin converting enzyme (ACE) inhibitor with a thiazepin ring, were studied in nephrectomised rats and compared with those of enalapril. The nephrectomised rats had much higher serum levels of creatinine (1.1 mg/dl) and blood urea nitrogen (73.5 mg/dl) than the control rats (0.6 and 18.6 mg/dl, respectively). Concentrations of RS-5139 and enalaprilat, the active metabolites of temocapril and enalapril, respectively, in the plasma, bile and urine were measured by the ACE inhibition assay or a gas chromatography-mass spectrometry system (GC/MS). There was no significant difference in the maximum plasma concentrations (Cmax) of RS-5139 between the nephrectomised (243.3 μg/L) and control rats (342.8 μg/L). On the other hand, the Cmax of enalaprilat in nephrectomised rats was significantly higher (399.3 μg/L) than in the control group (158.6 μg/L; p<0.05). Biliary excretion of RS-5139 was up to 79.2 and 81.8% in the control and nephrectomised groups, respectively, whereas the corresponding values for enalaprilat were only 7.7 and 12.2%. Urinary excretion of RS-5139 was only 4.7 and 3.8% in the control and nephrectomised rats, respectively, whereas the corresponding values for enalaprilat were 48.9 and 54.1%. These results show that a single dose of temocapril is preferentially excreted in bile and its elimination was unaffected by impaired renal function.

This is a preview of subscription content, log in to check access.

References

  1. Acosta JH. J Hypertension in chronic renal disease. Kidney International 22: 702–712, 1982

  2. Bonsnes RW, Taussky HH. On the colorimetric determination of creatinine by the Jaffé reaction. Journal of Biological Chemistry 158: 581, 1945

  3. Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7: S2–S11, 1985

  4. Carr RD, Cooper AE, Huchinson R, Mann J, O’Corner SE, et al. Preferential biliary elimination of FPL63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. British Journal of Pharmacology 100: 90–94, 1990

  5. Coulombe JJ, Favrean L. A new simple semicro ((?)) method for colorimetric determination of urea. Clinical Chemistry 9: 102–108, 1963

  6. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination in kinetics of captopril in patients with renal failure. Kidney International 25: 942–947, 1984

  7. Esumi Y, Takaichi M, Kakurai Y. The pharmacokinetics of SQ-14,225 (I): Absorption, excretion, and metabolism in rats. (In Japanese). Clinical Report 15: 4722–4730, 1981

  8. Giudicelli JF. Clinical pharmacology of enalapril. Presse Medicale 14: 2209–2211, 1985

  9. Gross DM, Sweet CS, Ulm EH, Backhand EP, Morris AA, et al. Effect of N-[(S)-1-Carboxy-3-Phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. Journal of Pharmacology and Experimental Therapeutics 216: 552–557, 1981

  10. Hui KK, Duchin KL, Klipalanili KJ, Chan D, Kramer PK, et al. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clinical Pharmacology and Therapeutics 49: 457–467, 1991

  11. Ikeda T, Tsubaki H, Mori I, Ida M, Yamamura N. Pharmacokinetic study on CS-622, a novel angiotensin converting enzyme inhibitor, and binding to pulmonary tissue. (In Japanese). Xenobiotic Metabolism and Disposition 5: 600, 1990

  12. Kawahara Y, Tokiwa H, Shimojo M. Determination of plasma angiotensin converting enzyme actiyity by high-performance liquid chromatography. Annual Report Sankyo Research Laboratory 37: 107–112, 1985

  13. Nakajima M, Hashimoto H, Oguchi S, Uematsu T, Takiguchi Y, et al. Phase I trial of a single oral dose of MK-421, a new angiotensin I converting enzyme inhibitor in healthy subjects. First report. (In Japanese). Japanese Pharmacology and Therapeutics 12: 3357–3374, 1984

  14. Nakajima M, Kanamaru M. Tolerance, pharmacokinetics and pharmacodynamics of single doses of cilazapril in normal volunteers. Journal of Clinical Therapeutics and Medicine 4: 2221–2247, 1988

  15. Ogihara T, Kumahara Y, Hosoki K, Hayashi K. Pharmacological study of alacepril, an angiotensin I converting enzyme inhibitor, in healthy volunteers. Current Therapeutic Research 42: 324–334, 1987

  16. Oguchi H, Miyasaka M, Koiwai T, Tokunaga T, Hora K, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clinical Pharmacokinetics 24: 421–427, 1993

  17. Oizumi K, Koike H, Sada T, Miyamoto M, Nishino H, et al. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. Japanese Journal of Pharmacology 48: 349–356, 1988

  18. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444, 1977

  19. Onoyama K, Hirakata H, Iseki K, Fujimi S, Omae T, et al. Blood concentration and urinary excretion of captopril (SQ-14225) in patients with chronic renal failure. Hypertension 3: 456–459, 1981

  20. Onoyama K, Nanishi H, Okuda S, Oh Y, Fujishima M, et al. Pharmacokinetics of derapril hydrochloride, angiotensin converting enzyme inhibitor, in patients with renal dysfunction. (In Japanese). Clinical Report 21: 1919–1932, 1987

  21. Roccella EJ. The 1988 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Archives of Internal Medicine 148: 1023–1038, 1988

  22. Shionoiri H, Miyazaki N, Yasuda G, Sugimoto K, Uneda S, et al. Blood concentration and urinary excretion of enalapril with chronic renal failure. Japanese Journal of Nephrology 27: 1291–1297, 1983

  23. Shioya H, Shimojo M, Kawahara Y. Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization. Journal of Chromatography 496: 129–135, 1989

  24. Suzuki H, Kawaratani T, Shioya H, Uji Y, Saruta T. Study on pharmacokinetics and blood pressure lowering effect of a biliary excreted angiotensin converting enzyme inhibitor, CS-622: single dose study. (In Japanese). Journal of Clinical Therapeutics and Medicine 8: 263–270, 1992

  25. Tateno M, Nakamura A. Clinical pharmacokinetics of CV-3317. (In Japanese). Japanese Pharmacology and Therapeutics 14: 4225–4331, 1986

  26. Tocco DJ, Deluna FA, Duncan AEW, Vassil TC, Ulm EH. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metabolism and Disposition 10: 15–19,1982

  27. Tokunaga S, Oguchi H, Higuchi M, Tokoo M, Miyasaka M et al. Antihypertensive effects and pharmacokinetics of temocapril, an angiotensin converting enzyme inhibitor with preferential biliary excretion, in patients with impaired renal function. Drug Investigation 7: 161–165, 1994

  28. Tsukamoto T, Yoshida K, Mitsuya M, Mituyai H, Naeshiro I. Metabolic fate of delapril hydrochloride (CV-3317), a new angiotensin converting enzyme inhibitor, in rats and dogs. (In Japanese). Japanese Pharmacology and Therapeutics 15: 1163–1193, 1987

  29. Yanagisawa H, Ishihara S, Ando A, Kanazaki T, Miyamoto S, et al. Angiotensin-converting enzyme inhibitors: Perhydro-1,4-thiazepin-5-one derivatives. Journal of Medicinal Chemistry 30: 1984–1991, 1987

Download references

Author information

Correspondence to Dr Makoto Higuchi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Higuchi, M., Oguchi, H., Terashima, M. et al. Single Dose Pharmacokinetics of Temocapril (CS-622), a Novel Angiotensin Converting Enzyme (ACE) Inhibitor, in Partially Nephrectomised Rats. Drug Invest 7, 191–199 (1994). https://doi.org/10.1007/BF03257410

Download citation

Keywords

  • Enalapril
  • Drug Invest
  • Biliary Excretion
  • Fosinopril
  • Enalaprilat